On Aug. 20, 2021, Regeneron announced that the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency had granted Conditional Marketing Authorization (CMA) for the casirivimab and imdevimab antibody cocktail, known as REGEN-COVﾙ in the U.S. and Ronapreveﾮ in the UK and other countries, to prevent and treat acute COVID-19 infection.

In addition to the CMA, which affects people in England, Scotland and Wales, the MHRA also authorized emergency supply of the antibody cocktail to prevent and treat acute COVID-19 infection for people in Northern Ireland.